The first International Forum on Cell and Gene Therapy was successfully held, and Professor Shi Yuanyuan, deputy director of the Cell Medicine Branch and chairman of Shenzhen Cell Valley, appeared at
The first International Forum on Cell and Gene Therapy was successfully held, and Professor Shi Yuanyuan, deputy director of the Cell Medicine Branch and chairman of Shenzhen Cell Valley, appeared at the 26th High-tech Fair with his team
From November 14-16, the first International Forum on Cell and Gene Therapy and the Second Forum on New Vaccine and Biologics Development, jointly organized by the Cell Medicine Branch of the China Food and Drug Enterprise Quality Safety Promotion Association (shortened as: China Food and Drug Safety Promotion Association), the Vaccine and Biologics Quality uation and Standards Professional Committee of the China Food and Drug Safety Promotion Association, the Guangdong Precision Medicine Application Society, and the Shenzhen Medical Association, along with the China Food and Drug Safety Promotion Associations Excellent Member Enterprises High-Tech Achievements Exhibition (referred to as "Two Forums and One Exhibition"), was successfully held. This grand event gathered outstanding scholars, entrepreneurs, and investors from the global biotechnology field, who collectively delved into the latest research achievements, industry trends, and future prospects of cell and gene therapy, injecting new momentum into the innovation-driven development of the biopharmaceutical industry and providing strong support for the continuous advancement of this field.
First International Forum on Cell and Gene Therapy
And the second Forum on the Development of New Vaccines and Biologics
On the morning of November 15, the opening ceremony of the "Two Sessions" was held in Hall 2 of the Shenzhen International Convention and Exhibition Center. The guests attending this conference included 11 academicians such as Zhang Xianen, Ji Guangju, Zhang Dan, Cai Zhiming, He Yuerong, Mao Zhenbin, Chen Zhinan, Mark A Kay, Wang Yutian, Lu Hongzhou, Shi Qiong, and over 100 experts, scholars, and technical personnel from major research institutions, universities, and the fields of cell gene therapy and vaccine development participated in the speech session, sharing their latest research findings and profound insights in the field of cell gene therapy.
Professor Shi Yuanyuan, deputy director of the Cell Medicine Branch and chairman of Shenzhen Cell Valley, presided over the opening ceremony and the release ceremony of the group standard as co-executive chairman of the forum.
Under the meticulous preparation and leadership of Professor Chen Junhui, the co-executive chair of the forum and a professor at Peking University Shenzhen Hospital, this conference was successfully held. Professor Chen gave a brief introduction to the organizational structure and hosting situation of this "Two Sessions". This forum consists of 1 main forum and 6 sub-forums, with a total number of participants exceeding 1500, making it a grand, highly professional, and widely influential technical conference.
Professor Lu Jiahai, co-executive chairman of the Forum and director of the Key Laboratory of Monitoring and uation of Quality of Vaccines and Biological Products, delivered a speech
Member of United Nations-International Academy of Ecological Life Safety Sciences and China Food and Drug Safety Promotion Association
President Mao Zhenbin delivered a speech
Liu Xuejun, director of the Health and Wellness Professional Committee of China Economic System Reform Research Association (left), and Professor Jiang Yuyang, deputy Director of Shenzhen Municipal Peoples Congress Standing Committee (right) delivered speeches
National group standard release ceremony
To promote the internationalization of cell and gene therapy in our country and fill the gap in the industry, the forum released the "Guidelines for the Preparation and Inspection of Human Mesenchymal Stem Cell Exosomes" led by Qingdao Haier Biotechnology Co., Ltd. and Peking University Shenzhen Hospital, as well as the "Guidelines for the Development of (Cell) Immunotherapy Products Based on mRNA-LNP Technology" led by the Key Laboratory of Quality Monitoring and uation of Vaccines and Biologics and Hunan Yuantai Biotechnology Co., Ltd. These releases are of great and far-reaching significance for breaking through the key technical bottlenecks that currently constrain industry development, seizing the commanding heights of the new round of technological and industrial revolutions, and advancing the industry towards a high-quality development direction.
The participants took a group photo with the representatives of the leading units
Main forum: Biomedical frontier innovation
Professor Wu Zhihong, director of the Expert Committee of the Cell Medicine Branch and professor at Peking Union Medical College Hospital
Wan Xiaochun, professor, Institute of Pharmaceutical Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Zhang Yong, researcher of National Clinical Research Center for Respiratory Diseases
Professor Zhang Xianen, Professor of the School of Synthetic Biology at Shenzhen University of Technology, Fellow of the Royal Society of Chemistry and member of the American Academy of Medical and Biological Engineering
Academician Mao Zhenbin, President of China Food and Drug Safety Promotion Association--Regulatory Science to Promote the Innovative Development of Advanced Medical Products
Professor Jiang Jianli, on behalf of Academician Chen Zhinan of the Chinese Academy of Engineering and Air Force Medical University--International Trends in Biomedical Technology and Bioeconomy
Dr. Jiang Ruhong, chairman of ASC Therapeutics, Inc., is the representative of the National Academy of Inventors and Prof. Mark Kay (Mark A Kay), MD, PhD, Stanford University School of Medicine
Professor Wang Jianjun from the Interdisciplinary Center of the Institute of Physics and Chemistry, Chinese Academy of Sciences
At the main forum, five top experts renowned in the field of biomedicine delivered in-depth speeches and exchanges on the theme of "Frontiers and Innovations in Biomedicine." They shared their latest research findings, innovative concepts, and future development trends from different perspectives. Through the insightful presentations by these experts, attendees gained a deep understanding of the latest developments in the biomedicine field, which also sparked profound reflections on technological innovation and industrial development.
Sub-forum 6: Cell preparation and vector technology forum
On the afternoon of November 15, the Cell Preparation and Vector Technology Forum was held as scheduled. The forum was kicked off by Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, and Dr. Xiang Hua, Co-founder and Vice President, who led a thorough discussion and exchange on the latest advancements and future directions of cell preparation and vector technology.
Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley, was invited to attend this forum and delivered an academic sharing on "Research Progress in Cell Immunotherapy". Professor Wang Jianxun, with his profound expertise in the field of immunology, engaged in in-depth discussions with attending experts and scholars, jointly exploring the latest trends in cell immunotherapy technology innovation and industry development. Additionally, the forum was honored to gather Academician Zhang Dan, Co-Chairman of Jiangsu Puxin Biopharma Co., Ltd., and other experts and scholars in the field of cell immunotherapy.
China Food and Drug Safety Promotion Association Excellent Member Enterprise High-tech Achievements Exhibition
The 26th China International High-Tech Fair (referred to as: Hi-Tech Fair) concluded successfully on November 16,2024. Among its highlights in the biopharmaceutical sector, the Cell and Gene Therapy and Vaccine Forum as well as the Excellent Member Enterprises High-Tech Achievements Exhibition were significant highlights of this years Hi-Tech Fair, attracting over 15,000 visitors who came to view and discuss business opportunities over the three days of the exhibition.
Shenzhen Cell Valley, as an excellent company in the field of cell and gene therapy, was invited to attend the conference. During the exhibition, Shenzhen Cell Valley received high attention from academicians and leaders who were touring the exhibition. Professor Shi Yuanyuan, the chairman, introduced in detail to them the core advantages and business scope of Shenzhen Cell Valley. As the only domestic provider capable of offering a one-stop solution for industrial-grade retroviral vector cell and gene therapy services, Shenzhen Cell Valley has established standardized, regulated, and industrialized production lines for GMP-grade retroviral vectors (RVV) and CAR-T cell products. They can provide services ranging from viral vector pipelines to cell product pipelines, as well as IIT/IND/NDA assistance and industry talent cultivation, establishing a mature full-process, one-stop service model.
Professor Shi Yuanyuan, chairman of the board, took a group photo with the visiting academicians and leaders
This grand event provides Shenzhen Cell Valley with a stage to showcase its strength and engage in exchanges and cooperation with relevant fields and internationally, fully demonstrating the development prospects of Shenzhen Cell Valley in the field of cell and gene therapy. Shenzhen Cell Valley will seize this opportunity to further accelerate its own technological innovation and market xpansion, contributing greater strength to the rapid development of the cell and gene therapy industry and enhancing human health levels.
From November 14-16, the first International Forum on Cell and Gene Therapy and the Second Forum on New Vaccine and Biologics Development, jointly organized by the Cell Medicine Branch of the China Food and Drug Enterprise Quality Safety Promotion Association (shortened as: China Food and Drug Safety Promotion Association), the Vaccine and Biologics Quality uation and Standards Professional Committee of the China Food and Drug Safety Promotion Association, the Guangdong Precision Medicine Application Society, and the Shenzhen Medical Association, along with the China Food and Drug Safety Promotion Associations Excellent Member Enterprises High-Tech Achievements Exhibition (referred to as "Two Forums and One Exhibition"), was successfully held. This grand event gathered outstanding scholars, entrepreneurs, and investors from the global biotechnology field, who collectively delved into the latest research achievements, industry trends, and future prospects of cell and gene therapy, injecting new momentum into the innovation-driven development of the biopharmaceutical industry and providing strong support for the continuous advancement of this field.
First International Forum on Cell and Gene Therapy
And the second Forum on the Development of New Vaccines and Biologics
On the morning of November 15, the opening ceremony of the "Two Sessions" was held in Hall 2 of the Shenzhen International Convention and Exhibition Center. The guests attending this conference included 11 academicians such as Zhang Xianen, Ji Guangju, Zhang Dan, Cai Zhiming, He Yuerong, Mao Zhenbin, Chen Zhinan, Mark A Kay, Wang Yutian, Lu Hongzhou, Shi Qiong, and over 100 experts, scholars, and technical personnel from major research institutions, universities, and the fields of cell gene therapy and vaccine development participated in the speech session, sharing their latest research findings and profound insights in the field of cell gene therapy.
Professor Shi Yuanyuan, deputy director of the Cell Medicine Branch and chairman of Shenzhen Cell Valley, presided over the opening ceremony and the release ceremony of the group standard as co-executive chairman of the forum.
Under the meticulous preparation and leadership of Professor Chen Junhui, the co-executive chair of the forum and a professor at Peking University Shenzhen Hospital, this conference was successfully held. Professor Chen gave a brief introduction to the organizational structure and hosting situation of this "Two Sessions". This forum consists of 1 main forum and 6 sub-forums, with a total number of participants exceeding 1500, making it a grand, highly professional, and widely influential technical conference.
Professor Lu Jiahai, co-executive chairman of the Forum and director of the Key Laboratory of Monitoring and uation of Quality of Vaccines and Biological Products, delivered a speech
Member of United Nations-International Academy of Ecological Life Safety Sciences and China Food and Drug Safety Promotion Association
President Mao Zhenbin delivered a speech
Liu Xuejun, director of the Health and Wellness Professional Committee of China Economic System Reform Research Association (left), and Professor Jiang Yuyang, deputy Director of Shenzhen Municipal Peoples Congress Standing Committee (right) delivered speeches
National group standard release ceremony
To promote the internationalization of cell and gene therapy in our country and fill the gap in the industry, the forum released the "Guidelines for the Preparation and Inspection of Human Mesenchymal Stem Cell Exosomes" led by Qingdao Haier Biotechnology Co., Ltd. and Peking University Shenzhen Hospital, as well as the "Guidelines for the Development of (Cell) Immunotherapy Products Based on mRNA-LNP Technology" led by the Key Laboratory of Quality Monitoring and uation of Vaccines and Biologics and Hunan Yuantai Biotechnology Co., Ltd. These releases are of great and far-reaching significance for breaking through the key technical bottlenecks that currently constrain industry development, seizing the commanding heights of the new round of technological and industrial revolutions, and advancing the industry towards a high-quality development direction.
The participants took a group photo with the representatives of the leading units
Main forum: Biomedical frontier innovation
Professor Wu Zhihong, director of the Expert Committee of the Cell Medicine Branch and professor at Peking Union Medical College Hospital
Wan Xiaochun, professor, Institute of Pharmaceutical Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Zhang Yong, researcher of National Clinical Research Center for Respiratory Diseases
Professor Zhang Xianen, Professor of the School of Synthetic Biology at Shenzhen University of Technology, Fellow of the Royal Society of Chemistry and member of the American Academy of Medical and Biological Engineering
Academician Mao Zhenbin, President of China Food and Drug Safety Promotion Association--Regulatory Science to Promote the Innovative Development of Advanced Medical Products
Professor Jiang Jianli, on behalf of Academician Chen Zhinan of the Chinese Academy of Engineering and Air Force Medical University--International Trends in Biomedical Technology and Bioeconomy
Dr. Jiang Ruhong, chairman of ASC Therapeutics, Inc., is the representative of the National Academy of Inventors and Prof. Mark Kay (Mark A Kay), MD, PhD, Stanford University School of Medicine
Professor Wang Jianjun from the Interdisciplinary Center of the Institute of Physics and Chemistry, Chinese Academy of Sciences
At the main forum, five top experts renowned in the field of biomedicine delivered in-depth speeches and exchanges on the theme of "Frontiers and Innovations in Biomedicine." They shared their latest research findings, innovative concepts, and future development trends from different perspectives. Through the insightful presentations by these experts, attendees gained a deep understanding of the latest developments in the biomedicine field, which also sparked profound reflections on technological innovation and industrial development.
Sub-forum 6: Cell preparation and vector technology forum
On the afternoon of November 15, the Cell Preparation and Vector Technology Forum was held as scheduled. The forum was kicked off by Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, and Dr. Xiang Hua, Co-founder and Vice President, who led a thorough discussion and exchange on the latest advancements and future directions of cell preparation and vector technology.
Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley, was invited to attend this forum and delivered an academic sharing on "Research Progress in Cell Immunotherapy". Professor Wang Jianxun, with his profound expertise in the field of immunology, engaged in in-depth discussions with attending experts and scholars, jointly exploring the latest trends in cell immunotherapy technology innovation and industry development. Additionally, the forum was honored to gather Academician Zhang Dan, Co-Chairman of Jiangsu Puxin Biopharma Co., Ltd., and other experts and scholars in the field of cell immunotherapy.
China Food and Drug Safety Promotion Association Excellent Member Enterprise High-tech Achievements ExhibitionThe 26th China International High-Tech Fair (referred to as: Hi-Tech Fair) concluded successfully on November 16,2024. Among its highlights in the biopharmaceutical sector, the Cell and Gene Therapy and Vaccine Forum as well as the Excellent Member Enterprises High-Tech Achievements Exhibition were significant highlights of this years Hi-Tech Fair, attracting over 15,000 visitors who came to view and discuss business opportunities over the three days of the exhibition.
Shenzhen Cell Valley, as an excellent company in the field of cell and gene therapy, was invited to attend the conference. During the exhibition, Shenzhen Cell Valley received high attention from academicians and leaders who were touring the exhibition. Professor Shi Yuanyuan, the chairman, introduced in detail to them the core advantages and business scope of Shenzhen Cell Valley. As the only domestic provider capable of offering a one-stop solution for industrial-grade retroviral vector cell and gene therapy services, Shenzhen Cell Valley has established standardized, regulated, and industrialized production lines for GMP-grade retroviral vectors (RVV) and CAR-T cell products. They can provide services ranging from viral vector pipelines to cell product pipelines, as well as IIT/IND/NDA assistance and industry talent cultivation, establishing a mature full-process, one-stop service model.
Professor Shi Yuanyuan, chairman of the board, took a group photo with the visiting academicians and leaders
This grand event provides Shenzhen Cell Valley with a stage to showcase its strength and engage in exchanges and cooperation with relevant fields and internationally, fully demonstrating the development prospects of Shenzhen Cell Valley in the field of cell and gene therapy. Shenzhen Cell Valley will seize this opportunity to further accelerate its own technological innovation and market xpansion, contributing greater strength to the rapid development of the cell and gene therapy industry and enhancing human health levels.
